Clinical trial
A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG)
A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG)
ClinicalTrials.gov ID: NCT05681715
Sponsor: UCB Biopharma SRL
Information provided by: UCB Biopharma SRL (Responsible Party)
Last Update Posted: 2023-09-01
Brief Summary:
The purpose of this study is to evaluate the ability of study participants with generalized Myasthenia Gravis (gMG) to successfully self-administer rozanolixizumab after training in the self-administration technique using the syringe driver and manual push methods.
OFFICIAL TITLE
An Open-label, Crossover Study to Evaluate Rozanolixizumab Self-administration by Study Participants With Generalized Myasthenia Gravis
INTERVENTION / TREATMENT
Drug: Rozanolixizumab
| Category | Value |
|---|---|
| Study Start (Actual) | 2023-04-17 |
| Primary Completion (Estimated) | 2024-07-04 |
| Study Completion (Estimated) | 2024-07-04 |
| Enrollment (Estimated) | 30 |
| Study Type | Interventional |
| Phase | Phase 3 |
| Other Study ID Numbers |
MG0020
2022-003870-21 (EudraCT Number)
|